safety of glp 1 receptor agonists GLP-1 for the Reduction Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes There has been a drug

Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M

Tirzepatide treatment was also associated with a reduction in waist circumference, systolic blood pressure, fasting insulin and plasma lipid concentrations as cardiometabolic risk parameters

PMID: 23728174 (This study is OPEN ACCESS if you would like to read it) The researchers gave exenatide (the Byetta formulation which is injected twice per day) to a group of 21 people with moderate Parkinsons and evaluated their progress over a 14 month period

What are the benefits of GLP-1 drugs

Important Note : Embody periodically runs limited-time intro promos (a Summer Start Promo offering a discount on the first month is live as of this update)